title: Pediatric lymphomas and histiocytic disorders of childhood.
abstract: Although there have been dramatic improvements in the treatment of children with non-hodgkin lymphoma, hodgkin lymphoma and histiocytic disorders over the past 3 decades, many still relapse or are refractory to primary therapy. In addition, late effects such as 2nd malignancies, cardiomyopathy and infertility remain a major concern. Thus, this review focuses on the current state of the science and, in particular, novel treatment strategies that are aimed at improving outcomes for all pediatric patients with lymphoma and histiocytic disorders while reducing treatment related morbidity.
authors.affiliation: Department of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, 1102 Bates St, Houston, TX 77030, USA.
authors.forename: Carl E
authors.initials: CE
authors.lastname: Allen
authors.affiliation: Herbert Irving Child and Adolescent Oncology Center, Morgan Stanley Children's Hospital, New York-Presbyterian, Columbia University Medical Center, 161 Fort Washington Ave, New York, NY 10032, USA.
authors.forename: Kara M
authors.initials: KM
authors.lastname: Kelly
authors.affiliation: Program for Cell Enhancement and Technologies for Immunotherapy, BMT Division, Department of Pediatrics, Children's National Health System, The George Washington University, 111 Michigan Avenue, Northwest, Washington, DC 20010, USA. Electronic address: cbollard@cnmc.org.
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Bollard
mesh_terms: D002648:Child; D006646:Histiocytosis, Langerhans-Cell / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D006801:Humans; D008223:Lymphoma / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*
keywords: Anaplastic large cell lymphoma (ALCL); Burkitt lymphoma (BL); Diffuse large B-cell lymphoma (DLBCL); Hodgkin lymphoma (HL); Juvenile xanthoganuloma (JXG); Langerhans cell histiocytosis (LCH); Posttransplant lymphoproliferative disease (PTLD); Rosai-Dorfman disease (RDD)